CAH · News & developments
CVS deal extends Cardinal’s visibility, but adds no disclosed growth engine
Cardinal Health announced a binding letter of intent to extend its existing pharmaceutical distribution agreement with CVS Health through June 30, 2032, while keeping the current scope of services. Cardinal also reaffirmed fiscal 2027 non-GAAP EPS guidance of $12.40 to $12.60, described as 13% to 15% growth, and long-term non-GAAP EPS growth guidance of 12% to 14%.
Why this matters
Keeping a major customer relationship in place for years can make distribution volumes easier to plan around, but the announcement offers no contract economics to show what Cardinal earns for that visibility. Because the service scope is unchanged, this is better read as continuity than incremental growth; the binding letter of intent is also not described as a completed definitive contract amendment. The reaffirmed EPS outlook therefore remains the more useful profitability signal, with further updates possible at the November 5 earnings call.
Written with AI from the linked sources and reviewed by a SageNoodle editor. How we work.